Montana...
I think he knows what he’s doing. The one thing that is absolutely true is this: we don’t know what we don’t know.
We have a bunch of prognosticators on our board. We’ve all filled that role from time to time. Including me.
We don’t know what JT has or had negotiated.
The truth is we know nothing.
We all got excited after he did his investor call “Spartan” speech.
Then, the generic is approved and now we are ready to show him the door.
Unless we are sitting at that conference table and participating in the decision making and strategy sessions, we know nothing. I am confident that JT will do everything he can to optimize shareholder value. In spite of Amarin constantly having to run through the gauntlet. There is nothing usual about Amarin. We have to accept the fact that when it comes to Amarin, we must expect the unexpected.
Again, it hasn’t come this far to only accept a fraction of its true worth.
Be well
News 
Market Data 
Discover 
